Intermediate Charcot-Marie-Tooth disease due to a novel Trp101Stop myelin protein zero mutation associated with debilitating neuropathic pain

Juan D Ramirez, Phillip R J Barnes, Kerry R Mills, David L H Bennett, Juan D Ramirez, Phillip R J Barnes, Kerry R Mills, David L H Bennett

Abstract

We report an English kindred affected across 4 generations with a hereditary neuropathy associated with debilitating neuropathic pain as the main clinical feature. The principal finding on clinical examination was sensory loss, and there was variable motor dysfunction. Electrophysiological studies revealed mild features of demyelination with median conduction velocity in the intermediate range. There was an autosomal-dominant pattern of inheritance, and genetic testing revealed a novel heterozygous Trp101X mutation in exon 3 coding for a portion of the extracellular domain of myelin protein zero. This is predicted to lead to premature termination of translation. Myelin protein zero is a key structural component of compact myelin, and over 100 mutations in this protein have been reported, which can give rise to neuropathies with either axonal, demyelinating, or intermediate features encompassing a wide range of severity. Chronic pain is an increasingly recognised sequela of certain hereditary neuropathies and may be musculoskeletal or neuropathic in origin. In this kindred, the neuropathy was relatively mild in severity, however, neuropathic pain was an important and disabling outcome.

Copyright © 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Family pedigree. Roman numerals represent the 1st to the 4th generation. Square, man; Circle, woman; Shaded symbol represents affected patients; Arrow points to the index case. Numbered subjects were seen by their health care team and are described in this report. Patients 5 and 2 were consented and entered the Pain in Neuropathy Study in which quantitative sensory testing was performed.
Fig. 2
Fig. 2
Quantitative sensory testing comparison of the lower limbs using z scores. (a) Patient 5. (b) Patient 2. Paradoxical heat sensations on Patient 5 were seen bilaterally (3 on each side); pain ratings did not show evidence of dynamic mechanical allodynia. CDT, cold-detection threshold; WDT, warm-detection threshold; TSL, thermal sensory limen; CPT, cold-pain threshold; HPT, heat-pain threshold; PPT, pressure-pain threshold; MPT, mechanical-pain threshold; MPS, mechanical-pain sensitivity; WUR, wind-up ratio; MDT, mechanical-detection threshold; VDT, vibration-detection threshold.
Fig. 3
Fig. 3
Immunohistochemistry. A maximum intensity projection of a confocal image of a lower-limb skin biopsy from a control subject (a) and Patient 5 (b) immunostained for protein gene product (PGP) 9.5 (red) to demonstrate axons and collagen type 4 (green) to show the basement membrane of the epidermis. There is no difference in the number of intraepidermal nerve fibres (arrows). (c-h) Confocal images of the dermis immunostained for PGP 9.5 [(c, f) red] and myelin basic protein [(d, g) MBP, green]. In Patient 5 (f, g, h), although numerous axons can be seen, there are no myelinated internodes, while in a control subject (c, d, e), numerous myelinated internodes were observed. Scale Bar: 50 μm.

References

    1. Atanasoski S., Scherer S.S., Nave K.A., Suter U. Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A. J Neurosci Res. 2002;67:443–449.
    1. Burns T.M., Phillips L.H., 2nd, Dimberg E.L., Vaught B.K., Klein C.J. Novel myelin protein zero mutation (Arg36Trp) in a patient with acute onset painful neuropathy. Neuromuscul Disord. 2006;16:308–310.
    1. Carter G.T., Jensen M.P., Galer B.S., Kraft G.H., Crabtree L.D., Beardsley R.M., Abresch R.T., Bird T.D. Neuropathic pain in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil. 1998;79:1560–1564.
    1. Dawkins J.L., Hulme D.J., Brahmbhatt S.B., Auer-Grumbach M., Nicholson G.A. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet. 2001;27:309–312.
    1. Dubner R., Sumino R., Wood W.I. A peripheral “cold” fiber population responsive to innocuous and noxious thermal stimuli applied to monkey’s face. J Neurophysiol. 1975;38:1373–1389.
    1. D’Urso D., Brophy P.J., Staugaitis S.M., Gillespie C.S., Frey A.B., Stempak J.G., Colman D.R. Protein zero of peripheral nerve myelin: biosynthesis, membrane insertion, and evidence for homotypic interaction. Neuron. 1990;4:449–460.
    1. Gemignani F., Melli G., Alfieri S., Inglese C., Marbini A. Sensory manifestations in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2004;9:7–14.
    1. Gillespie C.S., Sherman D.L., Fleetwood-Walker S.M., Cottrell D.F., Tait S., Garry E.M., Wallace V.C., Ure J., Griffiths I.R., Smith A., Brophy P.J. Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron. 2000;26:523–531.
    1. Grandis M., Vigo T., Passalacqua M., Jain M., Scazzola S., La Padula V., Brucal M., Benvenuto F., Nobbio L., Cadoni A., Mancardi G.L., Kamholz J., Shy M.E., Schenone A. Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Hum Mol Genet. 2008;17:1877–1889.
    1. Guilbot A., Williams A., Ravise N., Verny C., Brice A., Sherman D.L., Brophy P.J., LeGuern E., Delague V., Bareil C., Megarbane A., Claustres M. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet. 2001;10:415–421.
    1. Houlden H., King R., Blake J., Groves M., Love S., Woodward C., Hammans S., Nicoll J., Lennox G., O’Donovan D.G., Gabriel C., Thomas P.K., Reilly M.M. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I) Brain. 2006;129:411–425.
    1. Houlden H., King R.H., Muddle J.R., Warner T.T., Reilly M.M., Orrell R.W., Ginsberg L. A novel RAB7 mutation associated with ulcero-mutilating neuropathy. Ann Neurol. 2004;56:586–590.
    1. Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2010;15:79–92.
    1. Jung H., Toth P.T., White F.A., Miller R.J. Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J Neurochem. 2008;104:254–263.
    1. Lagueny A., Latour P., Vital A., Le Masson G., Rouanet M., Ferrer X., Vital C., Vandenberghe A. Mild recurrent neuropathy in CMT1B with a novel nonsense mutation in the extracellular domain of the MPZ gene. J Neurol Neurosurg Psychiatry. 2001;70:232–235.
    1. Lemke G., Lamar E., Patterson J. Isolation and analysis of the gene encoding peripheral myelin protein zero. Neuron. 1988;1:73–83.
    1. Martini R., Fischer S., Lopez-Vales R., David S. Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. Glia. 2008;56:1566–1577.
    1. Martini R., Schachner M. Molecular bases of myelin formation as revealed by investigations on mice deficient in glial cell surface molecules. Glia. 1997;19:298–310.
    1. Mogil J.S. Animal models of pain: progress and challenges. Nat Rev Neurosci. 2009;10:283–294.
    1. Pareyson D., Menichella D., Botti S., Sghirlanzoni A., Fallica E., Mora M., Ciano C., Shy M.E., Taroni F. Heterozygous null mutation in the P0 gene associated with mild Charcot-Marie-Tooth disease. Ann N Y Acad Sci. 1999;883:477–480.
    1. Piazza S., Baldinotti F., Fogli A., Conidi M.E., Michelucci A., Ienco E.C., Mancuso M., Simi P., Siciliano G. A new truncating MPZ mutation associated with a very mild CMT1 B phenotype. Neuromuscul Disord. 2010;20:817–819.
    1. Plante-Bordeneuve V., Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–1097.
    1. Provitera V., Nolano M., Pagano A., Caporaso G., Stancanelli A., Santoro L. Myelinated nerve endings in human skin. Muscle Nerve. 2007;35:767–775.
    1. Rolke R., Baron R., Maier C., Tolle T.R., Treede R.D., Beyer A., Binder A., Birbaumer N., Birklein F., Botefur I.C., Braune S., Flor H., Huge V., Klug R., Landwehrmeyer G.B., Magerl W., Maihofner C., Rolko C., Schaub C., Scherens A., Sprenger T., Valet M., Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006;123:231–243.
    1. Scherer S.S., Wrabetz L. Molecular mechanisms of inherited demyelinating neuropathies. Glia. 2008;56:1578–1589.
    1. Schneider-Gold C., Kotting J., Epplen J.T., Gold R., Gerding W.M. Unusual Charcot-Marie-Tooth phenotype due to a mutation within the intracellular domain of myelin protein zero. Muscle Nerve. 2010;41:550–554.
    1. Shy M.E. Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci. 2006;242:55–66.
    1. Shy M.E., Blake J., Krajewski K., Fuerst D.R., Laura M., Hahn A.F., Li J., Lewis R.A., Reilly M. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005;64:1209–1214.
    1. Shy M.E., Jani A., Krajewski K., Grandis M., Lewis R.A., Li J., Shy R.R., Balsamo J., Lilien J., Garbern J.Y., Kamholz J. Phenotypic clustering in MPZ mutations. Brain. 2004;127:371–384.
    1. Steck A.J., Erne B., Pareyson D., Sghirlanzoni A., Taroni F., Schaeren-Wiemers N. Normal expression of myelin protein zero with frame-shift mutation correlates with mild phenotype. J Peripher Nerv Syst. 2006;11:61–66.
    1. Takashima H., Boerkoel C.F., De Jonghe P., Ceuterick C., Martin J.J., Voit T., Schroder J.M., Williams A., Brophy P.J., Timmerman V., Lupski J.R. Periaxin mutations cause a broad spectrum of demyelinating neuropathies. Ann Neurol. 2002;51:709–715.
    1. Treede R.D., Jensen T.S., Campbell J.N., Cruccu G., Dostrovsky J.O., Griffin J.W., Hansson P., Hughes R., Nurmikko T., Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–1635.
    1. Verhoeven K., De Jonghe P., Coen K., Verpoorten N., Auer-Grumbach M., Kwon J.M., FitzPatrick D., Schmedding E., De Vriendt E., Jacobs A., Van Gerwen V., Wagner K., Hartung H.P., Timmerman V. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet. 2003;72:722–727.
    1. Wallace V.C., Cottrell D.F., Brophy P.J., Fleetwood-Walker S.M. Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci. 2003;23:3221–3233.
    1. Warner L.E., Hilz M.J., Appel S.H., Killian J.M., Kolodry E.H., Karpati G., Carpenter S., Watters G.V., Wheeler C., Witt D., Bodell A., Nelis E., Van Broeckhoven C., Lupski J.R. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron. 1996;17:451–460.
    1. Zarate Y.A., Hopkin R.J. Fabry’s disease. Lancet. 2008;372:1427–1435.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner